A Phase II Trial of OSI-774 in Patients With Hepatocellular or Biliary Carcinoma
Phase of Trial: Phase II
Latest Information Update: 03 Jun 2013
At a glance
- Drugs Erlotinib (Primary)
- Indications Biliary cancer; Liver cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 05 Dec 2012 Primary endpoint added as reported by ClinicalTrials.gov record.
- 16 Mar 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.